CD8A and hepatocellular carcinoma: In addition to these effects, patients with HCC usually accompanied by underlying liver disease could benefit from the additional anti-inflammatory effects of antiplatelet agents via various mechanisms, such as preventing the accumulation of CD8+ T-lymphocytes [7] and platelet-derived growth factor-β [22], resulting in reduced fibrosis and HCC.